Gary Nabel, ModeX Therapeutics CEO (Rob Tannenbaum for Endpoints News)

Ex-NIH, Sanofi lead­ers nab Mer­ck sup­port for their biotech’s Ep­stein-Barr vac­cine 

Gary Nabel, An­tho­ny Fau­ci and oth­er NIH lead­ers called for a vac­cine to pre­vent Ep­stein-Barr virus-as­so­ci­at­ed can­cers in 2011. Nabel went on to lead sci­en­tif­ic op­er­a­tions at Sanofi, where he worked with for­mer NIH di­rec­tor Elias Zer­houni on pro­grams that in­clud­ed ear­ly re­search on an EBV vac­cine.

Af­ter leav­ing the French Big Phar­ma, they formed a new biotech, Mod­eX Ther­a­peu­tics, and in-li­censed the Sanofi in­tel­lec­tu­al prop­er­ty on their EBV work. Now, they’re team­ing up with Mer­ck to bring the vac­cine can­di­date in­to the clin­ic next year for in­fec­tious mononu­cle­o­sis (com­mon­ly re­ferred to as mono), Nabel tells End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.